Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.
Recruitment status was Recruiting
The purpose of the study is to check whether development of depression as a side effect of interferon alpha treatment in chronic carriers of hepatitis C can be prevented by omega-3 fatty acids.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
|Official Title:||Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.|
- The effect of omega three fatty acids would be estimated through two questionnaires which filled by the patients monthly
- with the BDI questionnaire which estimates the level of depression of the patient and
- the SF36 questionnaire which provides information about the overall influence of a disease upon a patient's daily life and mental status.
- Secondary outcome measures include monthly results of biochemical and hematologic blood tests, including levels of:
|Study Start Date:||December 2006|
|Estimated Study Completion Date:||December 2007|
Omega-3 fatty acids are known as an alternative treatment for different conditions, including mental conditions, such as depression. We assume that combining omega-3 with the treatment by interferon alpha may prevent the development of depression, which is quite a common side effect of the interferon alpha.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00408304
|Bnai Zion Medical Center||Recruiting|
|Contact: Elad Schiff 97248359281 email@example.com|
|Principal Investigator: Elad Schiff|
|Principal Investigator:||Elad Schiff, MD||affiliated with Bnai Zion MC|